Welcome to our dedicated page for HALEON PLC SEC filings (Ticker: HLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HLNCF SEC filings page on Stock Titan provides access to U.S. regulatory disclosures related to Haleon plc, which files as a foreign private issuer and is listed on the London Stock Exchange and New York Stock Exchange under the symbol HLN. These filings are submitted on Form 20-F for annual reporting and Form 6-K for current reports under the Securities Exchange Act of 1934.
Haleon’s Form 6-K filings cover several important areas for investors. Some reports focus on operating model and strategy, such as the announcement of the evolution of its operating model in support of its "Win as One" strategy. These documents describe the creation of roles like Chief Growth Officer and Chief Transformation Officer, the formation of regional Operating Units, and the responsibilities of global functions.
Other 6-K filings relate to Director/PDMR Shareholding. These provide notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation, including acquisitions of partnership shares and awards of matching shares under Haleon’s Share Reward Plan, with details on the financial instruments and trading venue.
Haleon also files 6-K reports on Total Voting Rights and Capital, which set out the number of issued ordinary shares of £0.01 each, treasury shares and ordinary shares with voting rights. This information is relevant for shareholders and others with notification obligations under the UK FCA’s Disclosure Guidance and Transparency Rules.
On Stock Titan, users can review these Haleon filings in one place, with AI-powered summaries that explain the key points of each document, from strategic changes to insider transactions and share capital updates, helping to make complex regulatory text more accessible.
Haleon plc has made its preliminary full year results for the year ended 31 December 2025 available online and through the UK Financial Conduct Authority’s National Storage Mechanism. The statement can be accessed via the Haleon investor website and London Stock Exchange document link.
Reflecting strong free cash flow and organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share, a payout ratio of about 38% of 2025 adjusted earnings versus 37% in 2024. This includes a final dividend of 4.9p per share, subject to shareholder approval, with payment on 14 May 2026 to holders on the register as of 10 April 2026. The ex-dividend date is 9 April 2026 for ordinary shares and 10 April 2026 for ADSs, and DRIP elections are due by 24 April 2026. Haleon states it expects to grow its ordinary dividend at least in line with adjusted earnings.
A recorded results presentation by the CEO and CFO will be available from 7:00am GMT on 25 February 2026, followed by a Q&A call at 8:45am GMT with international dial-in access and a later archived webcast on the investor website.
Haleon plc reported routine share plan transactions by two senior executives under its Share Reward Plan. On 10 February 2026, General Counsel Adrian Morris acquired 31 ordinary shares at £3.956 as Partnership Shares and received 31 Matching Shares at no cost, for an aggregated volume of 62 shares. On the same date, President, Europe Jonathan Workman acquired 32 Partnership Shares at £3.956 and received 32 Matching Shares at no cost, an aggregated 64 shares. All transactions involved ordinary shares of £0.01 each, traded on the London Stock Exchange.
Wellington Management Group LLP and related entities report their ownership of Haleon plc common stock on an amended Schedule 13G. As of 12/31/2025, they beneficially own 443,046,686 shares, representing 4.97% of the class, with shared voting and dispositive power through investment adviser clients.
The securities are held in the ordinary course of business by Wellington-managed clients and are not held for the purpose of changing or influencing control of Haleon. No individual client is reported to hold more than five percent of the class.
Haleon plc has updated its share capital and voting rights information. As at 31 January 2026, the company has issued 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 shares are held in treasury. This leaves 8,906,796,528 ordinary shares with voting rights.
Shareholders and others with notification obligations under the FCA's Disclosure Guidance and Transparency Rules are instructed to use the voting-rights figure as the denominator when assessing whether they must report their holdings or changes in their interest in Haleon.
Haleon plc filed a report noting an additional external role for its Chief Financial Officer. Dawn Allen, Haleon’s CFO, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective 5 March 2026. She has already been serving as a Non-Executive Director of ITV and a member of its Audit & Risk Committee since 2 October 2023.
The update is described as a director declaration made in line with Listing Rule 6.4.9R(2). Haleon also reiterates that it is a global consumer health company with a portfolio of well-known brands including Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren.
Haleon plc outlined an evolution of its operating model to support its “Win as One” strategy, aiming to drive growth, productivity and culture, with changes expected to be implemented by mid-2026. The company has created a new Chief Growth Officer role that will oversee Category, Marketing and Strategy functions, plus a new global Commercial Excellence team, and will lead the growth and innovation agenda together with R&D, Supply Chain and new Operating Units.
Haleon is also reorganising into six Operating Units, splitting the current EMEA & LatAm region into Latin America, Middle East and Africa, and Europe, and establishing India Subcontinent as its own unit separate from Asia Pacific, while North America remains unchanged. In addition, a new Chief Transformation Officer will coordinate transformation across business processes, the operating model and technology. The CGO, CTO and each Operating Unit President will join the Executive Committee and report to CEO Brian McNamara. Further detail is expected with the Preliminary Full Year Results scheduled for 25 February 2026.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. On 9 December 2025, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 35 partnership shares in Haleon at a price of £3.57201 per ordinary share and received 35 matching shares at no cost. These ordinary shares have a nominal value of £0.01 each and are listed on the London Stock Exchange. The disclosure is made in line with UK Market Abuse Regulation requirements for transactions by persons discharging managerial responsibilities.
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reported PDMR share transactions under its Share Reward Plan. On 11 November 2025, Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 33 ordinary shares at £3.718992 and received 33 matching shares at £Nil on the London Stock Exchange.
These notifications were made in accordance with the UK Market Abuse Regulation and reflect routine participation in the company’s employee share plan.
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.